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Abstract The CRISPR system for gene editing can break, repair, and replace tar-
geted sections of DNA. Although CRISPR gene editing has important therapeutic
potential, it raises several ethical concerns. Some bioethicists worry CRISPR is a
prelude to a dystopian future, while others maintain it should not be feared because
it is analogous to past biotechnologies. In the scientific literature, CRISPR is often
discussed as a revolutionary technology. In this paper we unpack the framing of
CRISPR as a revolutionary technology and contrast it with framing it as a value-
threatening biotechnology or business-as-usual. By drawing on a comparison
between CRISPR and the Ford Model T, we argue CRISPR is revolutionary as a
product, process, and as a force for social change. This characterization of CRISPR
offers important conceptual clarity to the existing debates surrounding CRISPR. In
particular, conceptualizing CRISPR as a revolutionary technology structures regu-
latory goals with respect to this new technology. Revolutionary technologies have
characteristic patterns of implementation, entrenchment, and social impact. As such,
early identification of technologies as revolutionary may help construct more
nuanced and effective ethical frameworks for public policy.
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1 Introduction: the CRISPR controversy
Although genome editing itself is not new, the CRISPR system1 for gene editing has
elicited renewed excitement and fear over medical, ethical, and social implications
of this technology. In particular, in early 2015, the application of CRISPR on non-
viable human embryos sparked heated public debates regarding the appropriate uses
of gene editing (Liang et al. 2015; Baltimore et al. 2015a, b). Discussions about
CRISPR in recent months indicate an underlying disagreement among researchers
about the ethical and social implications of this technology. Some researchers worry
that CRISPR will lead to designer babies and eugenics, proliferate social injustice,
and risk disastrous changes to society and the environment (Lanphier et al. 2015;
Ledford 2015). These critics appeal to the long history of failed human interventions
as evidence that a tool with the breadth and power of CRISPR should be subject to
intense scrutiny and regulation. Others seem to characterize CRISPR as ‘just
another biotechnology’ (Harris 2016). These researchers downplay the concerns
about CRISPR research by analogy to once-feared biotechnologies, like in vitro
fertilization and cloning. These researchers argue the ethical concerns about
CRISPR are overblown because they are not new or are unlikely to come to pass
(Morange 2015). Instead, they emphasize the positive therapeutic potential of
CRISPR technology.
There are advantages and disadvantages to adopting either of these ethical
framings for CRISPR gene editing. For example, emphasizing the possible dangers
of CRISPR gene editing may help slow or eliminate dangerous practices, but it
might also hinder beneficial applications. Alternatively, the ‘just another biotech-
nology’ approach may open the door for beneficial CRISPR research, but ignore
potential bad consequences of the technology as well as the ways in which older
biotechnologies remain ethically controversial. Each approach foregrounds distinc-
tive issues and serves to shift the burden of proof to its deniers. The characterization
of CRISPR matters insofar as framing the ethical analyses also shapes the
development of this emerging technology.
There is an third way of framing of the CRISPR system. Several scientists have
referred to CRISPR as ‘groundbreaking,’ ‘revolutionary,’ and ‘disruptive’ (Barran-
gou 2014; Zhang and Zhou 2014; Kennedy and Cullen 2015; Ledford 2015;
Sontheimer and Barrangou 2015). Henry T. Greely recently characterized the
CRISPR system as ‘the Model T of genetics’ (Specter 2015). Framing the CRISPR
system as revolutionary presents an interesting alternative to the dystopia/business-
as-usual dichotomy. Revolutionary technologies follow similar patterns of imple-
mentation, entrenchment, and social impact while being a priori unpredictable in the
specifics of their consequences.
Science, Technology, and Society scholar David Collingridge poses a dilemma
for new technologies. Before the technology is developed and implemented, there is
1 CRISPR (clustered regularly interspaced short palindromic repeats) is a nucleic acid construct, Cas is
one of the associated families of enzymes (specifically nucleases), which can sever DNA strands in
desired locations, triggering cell-repair mechanisms. By providing replacement DNA to the cell,
researchers can effectively ‘edit’ genetic material. Unless the context calls for specificity, we will use ‘the
CRISPR system’ to refer to the enzyme-mediated gene-editing biotechnology.
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an information problem, as the potential impact cannot be easily predicted. But after
the technology becomes entrenched, society faces a power problem, as controlled
change becomes difficult (Collingridge 1980). If history is a guide, revolutionary
technologies have only a small window of time in which regulators can avert
potential problems in the transition from fragile-ideas-with-unknown-consequences
to known-and-difficult-to-regulate-industries (Collingridge 1980; Moor 2005). The
full spectrum of social and ethical implications of a new technology are unknowable
if each aspect of a new technology is addressed independently.
In this paper, we argue the CRISPR system is revolutionary and ought to be
conceptualized as such within media and research communities. Framing this
technology as such offers an important lens from which to assess the nuanced
ethical and social implications of CRISPR. In particular, the recognition of the
CRISPR system as a revolutionary technology will serve to emphasize the complex
and far-reaching potential of genome editing. We begin with a brief description of
revolutionary technologies to illustrate how they differ from normal technologies.
We then build on Greely’s comparison of the CRISPR system and the Model T in
order to illustrate how this new gene editing system is revolutionary. We explore
three distinct ways of understanding the CRISPR system as revolutionary, namely:
as a product with great versatility, as a speedy and affordable process, and as a
social force of great impact. Together, these three points of comparison show that
CRISPR gene editing is most fruitfully understood as revolutionary. We conclude
by arguing the CRISPR-as-revolutionary framing can guide inquiry and support
ethical deliberation and public policy with respect to CRISPR.
2 Background: CRISPR as a revolutionary biotechnology
A technological revolution can be defined as a quick change brought about by the
introduction of a new technology or a way of making prior technologies simpler,
accessible, or more affordable (Bostrom 2007, p. 129; Christenson 1997; Moor
2005, p. 114). Recent history is filled with such innovations: computers, cellular
phones, and social media are three recent examples out of hundreds. Such
innovations are distinctive with respect to their negative consequences for
established markets and value systems (Christenson 1997). The emergence of these
technologies may also raise policy vacuums in which policies (laws, rules, and
customs) developed under earlier paradigms no longer apply in the new situations
that occur as a result of adopting these technologies (Moor 2005, p. 115).
It may help to see how the CRISPR system fits into this characterization.
CRISPR technology, in many areas of science, is already entrenched as the go-to
method for gene editing because of its versatility, cost, and ease. In these areas, we
face a new technology’s power problem as introducing effective new regulations
would be difficult or ineffective. Consider the fact that when similar regulations
were introduced in the United States to curtail research on embryonic stem cells,
several top researchers emigrated to Singapore and other countries rather than cease
their work (Colman 2008; Dhar and Hsi-en Ho 2009).
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In other areas in which CRISPR is important, we are entering a new frontier that
is still being explored. This is especially true for more speculative uses of CRISPR,
such as de-extinction, controlled extinction, and encryption of hidden messages in
living tissue (see Charo and Greely 2015). Here we face the information problem for
new technologies, as we know relatively little about what new uses CRISPR may
have, how they could be implemented, or how they may impact society. The
harnessing of genetic changes will be guided by political, commercial, scientific,
and personal interests. It is impossible to know exactly how CRISPR will change the
world, but history teaches us the effects of revolutionary technologies will be
complex and far-reaching. If this is truly a revolutionary technology, ethicists and
regulators may soon confront wide, commercial, industrial, and personal use (Moor
2005).
CRISPR is of particular interest because of its speed, ease, and versatility of use.
Many researchers are optimistic about the potential therapeutic benefits of CRISPR
technology and anticipate that it will eventually be lead to treatments of various
human ailments, including AIDS, malaria, and cancer (Specter 2015). That such
wide-ranging therapies are being considered is evidence of the CRISPR system’s
revolutionary potential. But careful attention to the history of prior revolutionary
technologies ought to make us give pause; the benefit of hindsight brings into relief
what is likely to be quite opaque to people at the time.
It can occasionally be ambiguous whether the revolutionary technology is
understood as the product itself, how the product is made, or its impact. We
distinguish between these three different understandings. We will first present
Greely’s example of the Model T as a product (car), a process (the moving assembly
line), and by its social uptake (by inspiring a range of important social changes).
Next, we will see how these map onto the CRISPR system. We consider it as a kind
of revolutionary product (gene editing), as a process (its versatility and efficiency),
and finish by considering its social uptake. Although we consider each separately,
each of these conceptions overlaps and influences the others to a great extent.
3 The Model T revolution
What made the Model T so famous and influential was not that it was a particularly
good car; in fact, it had a number of design problems. For example, it never had turn
signals and it needed to go up steep hills in reverse (Duncan 2011, p. 82). Rather,
one sense in which the Model T is revolutionary is as an exemplary instance of a
revolutionary product: cars themselves. Womack et al. (1990) describe the
automobile as the machine that changed the world. Automobiles are versatile.
They offer improvements in the speed and capacity of any number of tasks
compared to walking or riding. Cars connect people and products across great
distances, dramatically shortening travel times. Originally viewed as a luxury item
(Duncan 2011, p. 9), the automobile brought a new source of social status, pleasure,
entertainment, and, in some cases, personal identity.
The Model T was the result of a truly revolutionary process: Henry Ford’s
careful attention to production flow and further development of the most important
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innovations in the history of manufacturing: interchangeable parts, vertical
integration, and the moving assembly line (Williams et al. 1992; Alizon et al.
2009). Earlier cars were designed and assembled by skilled craftspersons, so
relatively few were produced in the 20 years before Ford began his operation in
1908 (Duncan 2011). Assembly lines and interchangeable parts had been in use in
various industries for decades, and were in fact, also used by Oldsmobile, a
competitor. But Ford is known for introducing a moving assembly line, which
would bring the vehicle to workers, octupling their production rate. This meant that
thousands and, eventually, tens of thousands of cars could be produced—driving the
cost of cars down to the equivalent of a worker’s few months’ salary, $950 initially,
but eventually as low as $360 (Williams et al. 1992). Ford’s triumphant
development of the moving assembly line eventually became incorporated in many
other industries. There is a direct link between the process perfected by Ford in the
Model T and the unparalleled productivity of the United States in the middle part of
the 20th century. This is especially evident in the country’s unparalleled production
of wartime materiel and factory-raised food.
Finally, we can consider the Model T with respect to its revolutionary societal
impact. Although cars had existed for decades before the popularization of Model T,
walking and riding horses (or horse-drawn carriages) continued to be the main
modes of transportation. So even if cars were revolutionary as technology, they
weren’t revolutionary in terms of actual impact on people or the world. Ford is
known for manufacturing 15 million Model Ts in 20 years, more than all other
American carmakers combined (Alizon et al. 2009). At one point, nearly one in
every two cars sold in the world was a Model T. The Model T changed the way that
people got around. The Model T revolution had an enormous impact on individual
and family life. The affordability of the car meant that people could travel farther,
quicker, and more easily. This made doing errands, getting to work, and visiting
friends or family much easier. It also meant that families could live farther away
from work or the city. Paradoxically, the increased ease in transportation led to a
more sedentary lifestyle.
The Model T also had extreme economic consequences. To combat costly
employee turnover and forestall unionization, Henry Ford opted to pay his workers
an unparalleled $5 a day (Womack et al. 1990). Many historians now view this as
the beginning of the American middle class (Ingrassia 2008). As a result of the
Model T’s popularization of automobiles, entire areas of the economy were created
while others were devastated. The jobs cars took away were balanced by the jobs
created in new industries: hotels boomed as people traveled beyond their usual
haunts, new accessory markets flourished, and there arose an international demand
for rubber, steel, and oil (Sturgeon and Florida 2000). These had a profound, direct,
and lasting impact on nations in South America and the Middle East. Cars became
such a central part of the American identity that, 100 years later when American
automobile manufacturers were about to go bankrupt, the U.S. government gave the
industry billions of dollars to keep their doors open. In its peak, automobile
manufacturing in America was an economic powerhouse, making cities such as
Detroit enormously wealthy and influential. Due to technical constraints in shipping
vehicles, the car could be produced in Detroit, but had to be assembled in dozens of
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other cities, thus bringing an economic boost to a number of areas in the U.S. and a
number of other countries worldwide (Sturgeon and Florida 2000).
The Model T was advertised as the ‘‘Universal Car’’ and used as everything from
simple transportation to agricultural machinery (Kline and Pinch 1996, p. 785). For
example, aftermarket kits were created in order to transform Model Ts into sources
of power to run machinery and haul farm supplies. The Model T contributed to the
mechanization of farming. It also allowed for the easier and quicker movement of
agricultural goods between the farm and cities. The Model T also had a massive
environmental impact. Lead was introduced in the 1920s to improve performance,
which acutely poisoned the workers who produced it and settled into the bodies of
every organism on the planet (Nriagu 1990). Smoke from car exhaust contributed to
smog problems in cities around the world. The rubber industry in South America
was not only damaging to the locals, it also had a profound and permanent effect on
the landscape of the continent (Sturgeon and Florida 2000). Parking lots were built
to house cars and roads were built to ease interstate and international travel.
These lots and roads literally changed the landscape of the planet, interrupting local
flora and fauna.
In the next section, we similarly consider the CRISPR system as revolutionary
with regard to it as a product, a process, and its societal impact. In each, we explore
the ways this technology has and will continue to change the landscape of research,
agriculture, medicine, ecosystems, personal use, and military or government use.
4 The CRISPR revolution
4.1 A revolutionary product
Sometimes the CRISPR system is understood as merely a particularly effective
instance of gene editing, and the edited gene is what is considered revolutionary.
Gene editing is not new. Gene editing can be used to alter the genetic material in
any organism at any stage of development: somatic (body) cells to alter individual
organisms or germ (reproductive) cells to alter the genetic material of future
generations (Carroll 2014).
Because CRISPR and other techniques are able to affect any gene in any
organism, the possibility of editing genes is as versatile as the living world itself.
Genes edited by the CRISPR system are typically edited more accurately than those
edited by alternative methods. Stem cell researcher Chad Cowan pointed out that the
best result using the prior technology of TALENs was worse than the worst result
using CRISPR technology (Cowan 2015). Although Liang et al. (2015) reported that
‘‘CRISPR/Cas9 could effectively cleave the endogenous b-globin gene (HBB)….
[but] the efficiency of homologous recombination directed repair (HDR) of HBB
was low and the edited embryos were mosaic. … [with evidence of] untoward
mutations’’ (p. 363).
Gene editing has a forty-year history (Friedmann and Roblin 1972), but aside
from appearances in science fiction, most of the public is unaware of the actual
frequency and breadth of gene editing currently in use. In research contexts, the
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disruption or removal of genetic material (knockouts) in model organisms is most
familiar. By studying modified organisms that lack specific genes, scientists have
been able to infer functions for large parts of genomes. One gene-editing company
even boasts offering genetic knockouts of every gene in mice and rats (Sigma-
Aldrich 2011). In addition to genetic knockouts, scientists are able to insert genes
(knockins) and partially suppress genes (knockdowns). This research is merely a
new approach to the long history of breeding experiments in biology. Such research
has allowed an unprecedented level of understanding, prediction, and control of the
genomes of all living things. For example, researchers have been able to create a
living creature from synthetic parts, first accomplished with a parasitic bacterium in
2008 (Gibson et al. 2008).
Editing genes is not only important for scientific research, it has already
transformed agriculture. Agriculture is often an early adopter with respect to
biotechnologies (breeding, in vitro fertilization, and cloning). It is likely that the
CRISPR system will be safer for use in agriculture than current techniques, which
are less accurate, efficient, or scalable. In other words, researchers will be able to
edit plant and animal genomes with fewer potential side effects. Researchers are
now pursuing the use of gene editing to create hardier, better tasting, bigger, and
allergen-free crops (Gallo and Sayre 2009). They may also use genetic engineering
to modify animals for consumption. Agriculture is a fascinating test case in how the
public will respond to this technology, as demonstrated by the rate of concern for
genetically modified organisms (GMOs) by the lay public.
But much of the debate over edited genomes centers around issues in health care.
There is as much optimism about CRISPR-based gene editing as there was for the
Human Genome Project nearly two decades ago. We now know of a number of
diseases and syndromes which are caused by mutations to single genes, such as
Huntington’s Disease. Much of the excitement about the CRISPR system centers on
the perceived ease of treating such diseases or other diseases which can be treated
by simple modifications, as with HIV/AIDS which relies on a single cell receptor. In
some of these cases, gene editing may be able to offer simple and permanent cures.
Some countries have already approved gene therapy (Peng 2005; Wilson 2005; Ra¨ty
et al. 2008) and even successfully treated certain cancers using bone marrow
transplantation of edited cells (Reardon 2015). We have already seen a potential
therapy of a rare pancreatic disease marketed for 1,000,000 Euros (Kutter 2015). In
the United States, there are currently no gene therapy products for sale, although the
Center for Biologics Evaluation & Research (CBER) has received many applica-
tions (Ra¨ty et al. 2008; FDA 2015). Likely this is due to lessons from Jesse
Gelsinger, the first human to die as a result of gene therapy. Gelsinger had a severe
immune response to the virally transmitted gene therapy, which resulted in the
collapse of multiple organs. As a result, regulatory bodies became extremely
concerned with human gene therapy and most clinical applications were delayed or
canceled. In the response to this tragic situation, clinicians, scientists, internal
review boards, granting agencies, and regulatory agencies developed new policies to
address the concerns Gelsinger’s case raised.
With the new wave of genetic therapies, critics of health care uses raise familiar
concerns about inequity and disability rights, off-target effects, and permanent
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biological changes which may constitute eugenics. Such concerns did not come
to pass with earlier biotechnologies, such as IVF, as advocates of the business-
as-usual framing point out (Harris 2016). If anything, IVF babies are at a greater
risk for some ailments relative to the general population (Davies et al. 2012).
CRISPR advocates also point out that CRISPR researchers take issues like off-
target effects very seriously and continue to try address them (Zhang and Zhou
2014). Some scientists working on CRISPR also reject the characterization of
gene editing as an irreversible intervention (Specter 2015). Recent research on
evolutionary and developmental biology (‘evo-devo’) has emphasized that much
of biology occurs apart from (and interacts with) genetics (see Carroll 2008). So,
although genes edited early in development will produce more entrenched
changes in an organism, most replaced genes can simply be reversed if they
show themselves to be hazardous. For example, the vast majority of biological
sex characteristics are produced during development, so gene therapy of adults is
unlikely to greatly improve medical gender reassignment. Importantly, all sides
acknowledge the massive changes we have already seen with gene-editing
technologies and the CRISPR system is the latest and potentially the most
impactful.
4.2 A revolutionary process
The CRISPR system is another gene-editing technology, but it is not just another
technology. Early technologies took 2–3 years and $100,000 to develop single
organisms with single desired modification (Yeadon 2015). Zinc finger nucleases
(ZFNs), an early gene-editing technique, are *30 amino acids long and bind to
3-base pair triplets (Kennedy and Cullen 2015). ZFNs, when bound to other
molecules, can edit DNA with very little risk of off-target effects, but they are
not able to bind to all 3 base pair triplet combinations, are expensive, difficult,
and a proprietary product (Sander et al. 2011; Kennedy and Cullen 2015; Yeadon
2015). More recent biotechnologies like transcription activator-like effector
nucleases (TALENs) are cheaper and more effective, targeting individual bases
rather than longer sequences. Recently, TALENs were used to effectively treat a
young girl with Leukaemia (Reardon 2015). But each of these technologies is
still more difficult to engineer, less accurate, and less effective than the CRISPR
system.
The CRISPR system is composed of a guide RNA linked to an enzyme (typically
Cas9, though many others exist). Previous gene-editing technologies consist of
proteins specifically developed to target nucleotides or sets of nucleotides. Because
the Cas9 enzyme does not change from use to use, only the 20-nucleotide guide
RNA needs to be produced rather than the much larger, delicate, and cumbersome-
to-produce proteins used in ZFNs and TALENs. The fact that the associated RNA is
easily interchangeable makes the DNA targeting much easier and faster. In fact,
there are companies that can quickly deliver any requested RNA sequence, making
the whole process much simpler (Specter 2015). By making the process less
laborious and more efficient, CRISPR/Cas allows a wide variety of scientists to edit
genomes.
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As a gene-editing tool, the CRISPR system burst onto the scene in 2013 (Mali
et al. 2013; Jinek et al. 2013; Hwang et al. 2013; Jiang et al. 2013; Cong et al. 2013;
DiCarlo et al. 2013; Ding et al. 2013; Friedland et al. 2013; Gratz et al. 2013; Li
et al. 2013a, b, c; Wang et al. 2013; Nekrasov et al. 2013). Just last year, it attracted
significant public attention when researchers attempted to modify ‘non-viable’
human embryos in order to edit a gene responsible for b-thalassaemia, a potentially
fatal blood disorder (Liang et al. 2015). The controversy that developed afterward
has been fierce. CRISPR doubters worry research is proceeding at a quicker pace
than ethical deliberation (Hosman 2015).
There are now over two hundred patent applications which mention CRISPR and
at least four CRISPR-based biotechnology companies have opened, raising tens of
millions of dollars each (Ledford 2015). Given the availability, versatility, and
accessibility of the CRISPR system, it has spread quickly in the scientific
community, with tens of thousands of citations over hundreds of papers in only the
past few years. As a comparison, within a year of the first gene edited by CRISPR/
Cas, it became subject to more scientific articles than ZFNs and TALENs combined.
CRISPR technology has become so central in many areas of science that many
scientists working with the CRISPR system already view it as the new gold standard
for gene editing.
4.3 Revolutionary social impact
We have discussed how gene editing could treat any number of medical conditions,
considered some of the potential impacts on agriculture, and also discussed how the
CRISPR system has already become the gold standard in many areas of science.
Given the cost, speed, and versatility of CRISPR technology, many believe it will
impact many number of other areas of life. There are now companies marketing
CRISPR kits to the public. These kits allow people to genetically modify bacteria to
glow or change color (Chung 2015). Because biology is omnipresent in life, it is
possible for lay use of CRISPR technology to influence any number of areas of day-
to-day life, disrupting current markets even as it opens new ones. Intuitively, we
would expect the greatest impact to be in jobs that currently take long periods of
time to develop biological results: such as animal breeding, plant horticulture,
conservation of species, removal of pests, and the production of cultured foods such
as dairy and alcohol.
More broadly, Esvelt et al. (2014) suggest that CRISPR can be selectively used to
alter the traits and population size of organisms within ecosystems. Gene editing
might be used to control populations of species ecologists may call ‘invasive,’ such
as rats, cane toads, or lionfish. Esvelt et al. suggest that, unlike chemical or
biocontrol methods, CRISPR would be able to target a particular species and
eradicate it. For example, Anopheles stephensi mosquitoes carry a parasite that is
responsible for malaria, a disease that causes the deaths of over 500,000 people
every year (Esvelt et al. 2014). One proposal, which has now been enacted by
researchers (Gantz et al. 2015), involves creating a gene drive in mosquitoes that
could kill the parasite that infects mosquitoes and causes the spread of malaria.
Within a relatively short amount of time, it is conjectured that they will be able to
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drive the malaria-causing parasite extinct. This approach would be quick, effective,
and less toxic than chemical alternatives, which have been getting less effective as
mosquitos build a tolerance to them (Esvelt et al. 2014). Such an intervention could
save the lives of millions of people, mostly children under 5 in developing nations.
CRISPR could also be used to promote more sustainable agriculture by controlling
insect pests and reverse herbicide resistance in weeds. Critics maintain the
modification of organisms in open ecosystems is unwise and potentially dangerous
(Ledford 2015). Some are skeptical about the notion of Western people making
permanent interventions into the ecosystems of mostly developing countries, as the
history of such interventions is plagued with horrible consequences. It is important
to remember that all human interventions are necessarily value-laden. As we modify
the world, we inevitably try to change it into the world as we wish to see it.
Conversely, the Long Now Project has proposed using CRISPR technology for
the purposes of de-extinction (Sherkow and Greely 2013). The idea is simply that
we might be able to engineer embryos with the DNA of extinct species. This might
allow us to bring back such culturally significant species as the passenger pigeon,
dodo, and wooly mammoth. Such endeavors are both more plausible and justifiable
when they serve some environmental purpose. But this proposal has been suggested
before with earlier biotechnologies, like cloning. Outside of fictional dinosaur
amusement parks, it has never received uptake, likely due to technical limitations on
the range of organisms for which this would be feasible. Regardless of the
mechanism, critics challenge that resources are better used for the preservation of
current species (Zimmer 2013). They also caution against reintroducing extinct
species, especially when the relevant ecosystems have changed significantly:
species may simply go extinct again or even turn out to be invasive in their own
former environments! Regardless, future generations may see some limited use of
de-extinction or gene-editing-related species preservations, especially in environ-
ments in which human activity has recently driven a local species to extinction. The
ethical features of each scenario may differ, and policy decisions are likely to
require input from CRISPR experts, experts in ecology and evolution, policy
experts, local stakeholders, and ethicists.
We can imagine uses for CRISPR will only increase in frequency and creativity
(see Charo and Greely 2015), perhaps even involved in personal use. In our lifetime,
we may see foods or pets customized and marketed to suit individual’s whims.
Researchers have already proposed using CRISPR to modify pigs to develop
human-compatible organs (Yang et al. 2015). CRISPR could also be used to
genetically modify domestic pets to be more appealing to humans. For example,
Chinese researchers recently used gene editing to create ‘‘micro pigs’’ that would be
sold as pets (Li et al. 2014; Larson 2015). Their institute plans to sell the micro pigs
for US$1600. Customers would be able to custom order their pet micro pig with a
coat color and pattern of their choosing (Lewis 2015).
If any of these proposals materialize, there will be widespread political
ramifications. We have already seen this in the recent, international calls for a
moratorium on human germline editing, which may be perceived as targeting China
and the Chinese researchers who crossed this new frontier. China allowed gene
C. Mariscal, A. Petropanagos
123
therapies during a decade in which many other countries avoided their clinical use,
resulting in last year’s use of CRISPR on human embryos (Liang et al. 2015). In a
recent workshop on gene editing, Qi Zhou of the Chinese Academy of Sciences was
questioned at length about the nature of regulation in China. Many in the audience
were concerned to discover that regulations in China are unenforced (Zhou 2015).
As more uses for this technology arise and other nations become early adopters,
international agreements will become even more difficult to agree upon or enforce.
This will be especially difficult if new innovations can be monetized and result in
economic or political power for individual countries.
The use of CRISPR for military purposes is harder to assess and can easily lead to
paranoia. Thankfully, there are some reasonable conclusions to draw. Due to the
expertise needed to use the technology, it is unlikely, for instance, that the near future
will see CRISPR used for nefarious purposes in the hands of poorly funded extremist
groups. Nevertheless, some might fear the uses foreign governments may see for
CRISPR. While it is easy to imagine CRISPR being used to create a ‘super bug’—
gene editing has already been used to recreate a live polio virus (Specter 2015)—
such uses are impractical from a military perspective. Biological weapons are much
less predictable than traditional weapons because reproduction does not respect
national boundaries and evolution is a powerful, unpredictable, and largely
uncontrollable force (Mariscal 2015). While gene editing is unlikely to be of
strategic use, we should always remain aware of the potential for desperate,
incompetent, or terrorist acts using such a technology. We do not expect gene editing
to be used to enhance humans in the military, as more reliable and stable conventional
technologies are already replacing humans on the battlefield. We might, however, see
CRISPR-based therapies used for battlefield injuries. Among the more intriguing and
plausible options are the use of CRISPR to label organisms or otherwise encode
unbreakable, untraceable messages in the DNA of living tissue (Brunet 2016),
though one may doubt the frequency in which such techniques may be necessary.
The detection of edited genes will be essential in such a scenario, though methods for
doing it quickly and reliably may still be far off in the future.
5 Lessons from hindsight
What do we learn from the Model T? How would the world have looked differently
if we thought about the far and wide-reaching implications of revolutionary
technologies as they were first introduced? Likely, the most important action would
be a continued, critical evaluation of the technology to address emerging problems
before they become entrenched. Rather than emerging in the late 1960s, suppose a
Taft or Wilson administration created a Department of Transportation and imbued it
with regulatory powers. Such a department would likely have foreseen some
problems early on: traffic and city planning, collisions, car safety, and possibly the
toxicity of lead in gasoline. Other problems may have been missed—air pollution,
possibly climate change, and possibly oil demand as a driver of geopolitical strife.
Such a department would also have focused on issues we no longer regard as
problematic—the fate of the horse industry, the shift away from widespread public
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use of railroads, and the cost of redesigning cities and infrastructure. Nevertheless, it
would have engaged with new uses and discoveries of automobiles as they emerged,
rather than decades later after many corporations had entrenched interests in
maintaining the status quo.
A similar department or organization with respect to gene editing may have
mixed outcomes. In general, it could regulate the types of research or clinical
applications of CRISPR that are permissible. Such a department could also help to
ensure the just and equitable distribution of the benefits resulting from CRISPR and
enact barriers or restrictions on the commercialization of this technology. Currently,
a number of organizations are paying close attention to CRISPR, including scientific
organizations like the U.S. and Chinese National Academies of Science, media like
the New Yorker (Specter 2015), regulatory agencies like the FDA’s Center for
Biologics Evaluation & Research (FDA 2015), and watchdog groups like the
International Center for Technology Assessment. There is no centralized body to
assess such technologies and there is likely a wide range of applications of CRISPR
work that may fall in a ‘regulatory vacuum’ (Moor 2005). Recently, the US
Department of Agriculture (USDA) declined to regulate CRISPR-modified mush-
rooms due to a technical loophole (Waltz 2016). Under USDA regulations, GMOs
must contain foreign DNA from plant ‘pests.’ While such DNA was needed for
genetically modifying organisms when the regulations were written in the 1980s, it
is no longer necessary. The USDA plans to overhaul its regulations over the next
decade and many goods will likely make it to the market in the meantime. The
environmental, social, economic, and ethical implications of using CRISPR on
animal and other living cells cannot be bound by national borders. The globalized
nature of science and technology necessitates an international approach to CRISPR
technology, so international cooperation is needed for any ethical regulation and
provision of CRISPR.
As we remarked in the introduction, revolutions have unpredictable consequences
even as they have predictable patterns of disruption and entrenchment. They rarely
result in the best or worst-case scenarios envisioned at the time. Nevertheless, it is
likely society will mishandle some of the effects of CRISPR. We know from the
history of revolutionary technologies like the Model T that we will not know a
technology’s social and ethical implications if we address each issue indepen-
dently. Consequently, an intellectually honest, historically informed approach
suggests we should develop a continuous engagement with the technology, ideally
in the form of a multidisciplinary, internationally respected body with some amount
of regulatory oversight.
6 Conclusion: future directions
The inevitable normalization of CRISPR gene editing will have far reaching
implications for all areas of life. CRISPR system is a revolutionary biotechnology
with a range of impact broader than any other biotechnology in recent memory.
Recognizing this fact will facilitate a broad range of ethical inquiry and caution in
what is best described as a social experiment. Like the Model T was in its time,
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CRISPR is easier, more accessible, and more versatile than the technologies it is
disrupting. This understanding of CRISPR reveals the need for continuous,
interdisciplinary, and international oversight. This should consist of experts in the
relevant areas (synthetic biologists, medical doctors, ecologists, economists,
ethicists, public policy experts, etc.) as well as the stakeholders in any proposed
interventions (scientific organizations, pharmaceutical companies, disability rights
advocates, environmentalists, the public, etc.). While this may be difficult now, it
will become impossible as the technology becomes socially entrenched. As such, it
is important for scientists, media, and policy-makers to move forward pushing for as
much of a unified front as possible.
The way we conceptually frame tools and technologies can hinder or support
ethical inquiry. When we view them as foreshadowing grim dystopias, we
foreground stronger regulatory oversight and an abandonment of current lines of
inquiry. When we view them as business-as-usual, we assume regulators should not
reevaluate the technology or that negative consequences have, are, or will be
adequately addressed. Each framework alienates advocates of the other. Each side
may view the other as naı¨ve and judge the other position based on its loudest, least
thoughtful advocates. Furthermore, with CRISPR, both approaches overemphasize
certain uses: human evolution and equity versus medical therapies and scientific
understanding. It is our hope that taking the CRISPR-as-revolutionary framework
seriously will highlight the promise and peril of this biotechnology without
overemphasizing either.
Hindsight is a privilege. Looking back at the Model T we are reminded of both
the benefits and harms of technological revolutions. CRISPR has myriad applica-
tions: scientific discovery, medicine, agriculture, ecology, commerce, military, etc.
But any human intervention in the world reflects our understanding of it as well as
our underlying values. Because of the unprecedented versatility, ease, and speed of
this technique, there is a need for ongoing public debate on the future direction of
CRISPR research and applications. Insofar as CRISPR is a revolutionary
technology, the ethical development, implementation, and provision of CRISPR
requires early regulatory oversight and attention to its far-reaching global
implications.
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